Literature DB >> 27566747

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.

Mar Tintore1, Susana Otero-Romero2, Jordi Río2, Georgina Arrambide2, Berta Pujal2, Carmen Tur2, Ingrid Galán2, Manuel Comabella2, Carlos Nos2, María Jesús Arévalo2, Angela Vidal-Jordana2, Joaquin Castilló2, Breogán Rodríguez-Acevedo2, Luciana Midaglia2, Raquel Mitjana2, Cristina Auger2, Jaume Sastre-Garriga2, Àlex Rovira2, Xavier Montalban2.   

Abstract

OBJECTIVE: To study the contribution of the symptomatic lesion in establishing multiple sclerosis (MS) diagnosis and prognosis.
METHODS: We performed an observational study based on a prospective clinically isolated syndrome (CIS) cohort of 1,107 patients recruited for clinical and brain MRI follow-up from 1995 to 2014. Eligible patients (n = 954) were divided into 4 groups according to baseline MRI: patients with a normal MRI (n = 290); patients with a single asymptomatic lesion (n = 18); patients with a single cord/brainstem symptomatic lesion (n = 35); and patients with more than 1 lesion (n = 611). For each group, we studied the risk of second attack, with 2005 McDonald MS and Expanded Disability Status Scale 3.0, using univariable and multivariable regression models adjusted by age, sex, oligoclonal bands, and disease-modifying treatments. We tested the diagnostic performance of a modified dissemination in space (DIS) criterion that includes symptomatic lesions in the total count and compared it to the DIS criteria (at least 1 asymptomatic lesion in at least 2 of the 4 MS characteristic MS locations) for all patients and for the subgroup of patients with brainstem or spinal cord topography.
RESULTS: Patients with a cord/brainstem single symptomatic lesion have a higher risk of second attack and disability accumulation than patients with 0 lesions but have a similar risk compared to patients with 1 asymptomatic lesion. Diagnostic properties are reasonably maintained when the symptomatic lesion qualifies for DIS.
CONCLUSIONS: Despite the recommendations of the 2010 McDonald criteria, symptomatic lesions should be taken into account when considering the diagnosis and prognosis of patients with CIS.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27566747     DOI: 10.1212/WNL.0000000000003144

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.

Authors:  Andrew J Solomon; Robert T Naismith; Anne H Cross
Journal:  Neurology       Date:  2018-10-31       Impact factor: 9.910

2.  Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis.

Authors:  Wallace J Brownlee; Katherine A Miszkiel; Carmen Tur; Frederik Barkhof; David H Miller; Olga Ciccarelli
Journal:  Neurology       Date:  2018-08-17       Impact factor: 9.910

Review 3.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

4.  Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis.

Authors:  Vittorio Mantero; Lucia Abate; Roberto Balgera; Loredana La Mantia; Andrea Salmaggi
Journal:  J Clin Neurol       Date:  2018-07       Impact factor: 3.077

5.  Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Authors:  Marloes Hj Hagens; Jessica Burggraaff; Iris D Kilsdonk; Serena Ruggieri; Sara Collorone; Rosa Cortese; Niamh Cawley; Emilia Sbardella; Michaela Andelova; Michael Amann; Johanna M Lieb; Patrizia Pantano; Birgit I Lissenberg-Witte; Joep Killestein; Celia Oreja-Guevara; Jens Wuerfel; Olga Ciccarelli; Claudio Gasperini; Carsten Lukas; Alex Rovira; Frederik Barkhof; Mike P Wattjes
Journal:  Mult Scler       Date:  2018-01-12       Impact factor: 6.312

Review 6.  Advances in spinal cord imaging in multiple sclerosis.

Authors:  Marcello Moccia; Serena Ruggieri; Antonio Ianniello; Ahmed Toosy; Carlo Pozzilli; Olga Ciccarelli
Journal:  Ther Adv Neurol Disord       Date:  2019-04-22       Impact factor: 6.570

Review 7.  The multiple sclerosis prodrome.

Authors:  Naila Makhani; Helen Tremlett
Journal:  Nat Rev Neurol       Date:  2021-06-21       Impact factor: 42.937

8.  Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

Authors:  Georgina Arrambide; Mar Tintore; Cristina Auger; Jordi Río; Joaquín Castilló; Angela Vidal-Jordana; Ingrid Galán; Carlos Nos; Manuel Comabella; Raquel Mitjana; Patricia Mulero; Andrea de Barros; Breogán Rodríguez-Acevedo; Luciana Midaglia; Jaume Sastre-Garriga; Alex Rovira; Xavier Montalban
Journal:  Neurology       Date:  2017-11-03       Impact factor: 9.910

Review 9.  Cerebellum and neurodegenerative diseases: Beyond conventional magnetic resonance imaging.

Authors:  Enricomaria Mormina; Maria Petracca; Giulia Bommarito; Niccolò Piaggio; Sirio Cocozza; Matilde Inglese
Journal:  World J Radiol       Date:  2017-10-28

10.  Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.

Authors:  Emma Rathbone; Lindsay Durant; James Kinsella; Antony R Parker; Ghaniah Hassan-Smith; Michael R Douglas; S John Curnow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-05-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.